AnaptysBio (NASDAQ:ANAB) Now Covered by Wolfe Research

Stock analysts at Wolfe Research began coverage on shares of AnaptysBio (NASDAQ:ANAB - Get Free Report) in a note issued to investors on Tuesday, MarketBeat reports. The brokerage set an "outperform" rating and a $25.00 price target on the biotechnology company's stock. Wolfe Research's target price suggests a potential upside of 71.47% from the company's current price.

Several other research analysts have also commented on the stock. BTIG Research lowered shares of AnaptysBio from a "buy" rating to a "neutral" rating in a research note on Monday, December 2nd. Wedbush reissued an "outperform" rating and issued a $40.00 price target on shares of AnaptysBio in a research report on Monday. Wells Fargo & Company cut their price objective on AnaptysBio from $56.00 to $40.00 and set an "overweight" rating on the stock in a research report on Thursday, December 12th. JPMorgan Chase & Co. decreased their target price on AnaptysBio from $66.00 to $36.00 and set an "overweight" rating for the company in a report on Thursday, December 19th. Finally, Guggenheim cut their price target on AnaptysBio from $90.00 to $36.00 and set a "buy" rating on the stock in a report on Thursday, December 12th. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.08.

AnaptysBio Price Performance

Shares of ANAB stock traded down $1.50 during trading on Tuesday, hitting $14.58. 522,893 shares of the stock traded hands, compared to its average volume of 700,012. The firm's fifty day moving average price is $16.69 and its 200-day moving average price is $26.62. AnaptysBio has a 52-week low of $12.51 and a 52-week high of $41.31. The firm has a market capitalization of $443.67 million and a P/E ratio of -2.40.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. As a group, equities research analysts expect that AnaptysBio will post -6.08 earnings per share for the current year.

Insider Buying and Selling at AnaptysBio

In other news, Director Ecor1 Capital, Llc purchased 65,184 shares of the company's stock in a transaction that occurred on Monday, December 30th. The shares were purchased at an average price of $12.92 per share, for a total transaction of $842,177.28. Following the purchase, the director now directly owns 7,860,180 shares of the company's stock, valued at $101,553,525.60. This represents a 0.84 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 33.70% of the stock is currently owned by insiders.

Institutional Trading of AnaptysBio

Several institutional investors and hedge funds have recently bought and sold shares of ANAB. FMR LLC grew its position in AnaptysBio by 15.3% during the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company's stock worth $110,857,000 after purchasing an additional 438,557 shares during the last quarter. Frazier Life Sciences Management L.P. grew its holdings in shares of AnaptysBio by 2.0% during the third quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company's stock worth $74,008,000 after buying an additional 43,598 shares during the last quarter. Assenagon Asset Management S.A. increased its position in AnaptysBio by 55.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company's stock valued at $15,927,000 after acquiring an additional 168,813 shares during the period. Geode Capital Management LLC raised its stake in AnaptysBio by 3.0% during the 3rd quarter. Geode Capital Management LLC now owns 465,401 shares of the biotechnology company's stock valued at $15,594,000 after acquiring an additional 13,336 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its position in AnaptysBio by 41.0% during the 4th quarter. Victory Capital Management Inc. now owns 334,450 shares of the biotechnology company's stock worth $4,428,000 after acquiring an additional 97,200 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.